Navigating the Ever-evolving Pandemic Landscape:
Preventing Disease Progression in High-Risk COVID-19 Outpatients
Smarter in Minutes #5: Molnupiravir
This activity is jointly provided by National Jewish Health and Bonum CE.
This program has been supported by an independent educational grant from Pfizer.
Program Overview
The mortality rate for COVID-19 remains high, especially in older patients and those with comorbidities. Research into treatment protocols and therapeutic agents has progressed at an unprecedented pace, and clinical practice guidelines are constantly being updated, necessitating regular training for clinicians. Furthermore, the rapid pace of COVID-19 research and the demands the pandemic has put on the healthcare system may result in clinicians having difficulty keeping up with the latest evidence and constant changes in the clinical practice guidelines.
The goal of this proposed educational initiative is to improve the familiarity of health care practitioners (HCPs) with the evidence supporting the use of antivirals in the outpatient setting. This short, Smarter in Minutes episode focuses key considerations for molnupiravir in the treatment of COVID-19.
Faculty
Dayna McManus, PharmD (co-chair)
Pharmacy Supervisor, Infectious Diseases
Director, PGY2 Infectious Disease Pharmacy Residency
Yale New Haven Hospital
New Haven, CT
Natasha Bhuyan, MD (guest faculty)
Assistant Clinical Professor
Family Community & Preventive Medicine
University of Arizona
Phoenix, AZ
Target Audience
This program is intended for geriatricians, primary care physicians (PCPs), internal medicine, family practice, pharmacists, nurse practitioners (NPs), physician’s assistants (PAs), nurses and other members of the allied health care team involved in, or interested in, education regarding COVID-19 therapeutics.
Learning Objectives
After completing this activity series, the participant should be better able to:
APPLY the efficacy and safety evidence for the use of antivirals in high-risk patients with mild-to-moderate COVID-19 to prevent disease progression
SELECT the appropriate therapeutic strategy to prevent COVID-19 disease progression in at-risk outpatients based on the latest guidelines
Disclosure of Relevant Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
-
Natasha Bhuyan, MD
Nothing to disclose
Dayna McManus, PharmD
Nothing to disclose -
-
National Jewish Health and Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.
Certification
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Jewish Health and Bonum Continuing Education, LLC. National Jewish Health is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
National Jewish Health designates this < activity type> for a maximum of 0.5 AMA PRA Category 1 Credit/s™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
European Physicians
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.
Instructions to Receive Credit & Fee Information
In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 75% on the post-test, complete the evaluation and application for credit form.
There is no fee to participate in this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NJH, collaborators, and faculty on this program do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimers
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
System Requirements
All Bonum CE digital activities require the following hardware/software to view and participate:
Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)
PowerPoint and/or a PDF viewer may be required on some activities
We recommend a minimum of:
128MB RAM
Processor speed of 500MHz or higher
800x600 color monitor
Video or graphics card
Sound card and speakers
To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.
Contact Information
For information about the accreditation of this program, please contact the Office of Professional Education at NJH at proed@njhealth.org.
Release date: November 6, 2023
Expiration date: November 6, 2024
Estimated time to complete activity: 30 minutes